Filing Flows › Comparisons › URGN vs PHAT
UroGen Pharma vs Phathom Pharmaceuticals: URGN and PHAT compared
UroGen Pharma is the larger company: $89.0M of revenue in its latest quarter (Q3 2026) against $84.7M for Phathom Pharmaceuticals (Q3 2026). UroGen Pharma is growing faster (+224% against +71% a year earlier). UroGen Pharma is more profitable, with an operating margin of 9.4% against -0.1%.
Where the money goes: URGN and PHAT
UroGen Pharma (URGN) · Q3 2026
UroGen Pharma, Q3 2026: revenue $89.0M (+224% year over year), operating margin 9.4%, net loss $1.5M, operating cash flow −$15.2M. The chart follows the revenue to costs, profit and cash.
Phathom Pharmaceuticals (PHAT) · Q3 2026
Phathom Pharmaceuticals, Q3 2026: revenue $84.7M (+71% year over year), operating margin -0.1%, net loss $13.9M, operating cash flow $1.8M. The chart follows the revenue to costs, profit and cash.
| UroGen Pharma (URGN) | Phathom Pharmaceuticals (PHAT) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $89.0M | $84.7M |
| Revenue growth, Y/Y | +224% | +71% |
| Operating margin | 9.4% | -0.1% |
| Net earnings | −$1.5M | −$13.9M |
| Net margin | -1.6% | -16.4% |
| Operating cash flow | −$15.2M | $1.8M |
| Free cash flow | — | $1.7M |
Where the revenue comes from
UroGen Pharma
- Zusduri: $68.0M (76%)
- Jelmyto: $21.0M (24%)
Questions
Which is bigger, UroGen Pharma or Phathom Pharmaceuticals?
UroGen Pharma is the larger company: $89.0M of revenue in its latest quarter (Q3 2026) against $84.7M for Phathom Pharmaceuticals (Q3 2026).
Is UroGen Pharma or Phathom Pharmaceuticals growing faster?
UroGen Pharma is growing faster (+224% against +71% a year earlier).
Which is more profitable, UroGen Pharma or Phathom Pharmaceuticals?
UroGen Pharma is more profitable, with an operating margin of 9.4% against -0.1%.
More: UroGen Pharma earnings · how UroGen Pharma makes money · Phathom Pharmaceuticals earnings · how Phathom Pharmaceuticals makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 4, 2026; 10-Q filed Oct 29, 2026). Fiscal quarters can end on different dates. Not investment advice.